Urica Therapeutics

Executive Summary

Urica Therapeutics is a clinical-stage biopharmaceutical company originally focused on developing novel therapies for hyperuricemia and related metabolic disorders. Its primary asset, dotinurad (a URAT1 inhibitor), was transferred to Crystalys Therapeutics, leaving Urica without an active pipeline. The company now operates as a majority-owned subsidiary of Fortress Biotech, Inc., and its future depends on potential new asset in-licensing or continued support from its parent. The hyperuricemia market is competitive, with established therapies like febuxostat and newer entrants. Without a clear pipeline or disclosed financials, Urica's standalone value proposition is limited, and its strategic direction remains uncertain. The company is categorized as Phase 3 based on historical development, but it currently lacks clinical-stage programs.

Upcoming Catalysts (preview)

• TBDAnnouncement of new pipeline asset in-licensing or acquisition20% success
• Q3 2026Clinical data readout from Crystalys Therapeutics on dotinurad (indirect catalyst)30% success
• TBDCorporate restructuring or spin-off from Fortress Biotech15% success